Effect of Sacubitril/Valsartan on serum agglutinin and SIRT6 in patients with coronary atherosclerotic heart disease complicated with acute heart failure

WANG Hao; ZHANG Yi; ZHOU Peng

doi:10.13431/j.cnki.immunol.j.20250108

Abstract：Objective To investigate the effects of Sacubitril/Valsartan(SV)on serum agglutinin and Silent Information Regulator Transporter 6(SIRT6)in patients with coronary atherosclerotic heart disease(CAHD)complicated with acute heart failure(AHF).Methods One hundred and twenty-two patients with CAHD complicated with AHF admitted from January 2023 to May 2024 were selected and divided into control group(n=61)and observation group(n=61)by random number table method.Both groups were given conventional treatment,the control group was given Candesartan Cilexetil tablets,and the observation group was given SV.The clinical efficacy,disease-related indicators,cardiac function indicators[left ventricular ejection fraction(LVEF),left ventricular end-diastolic diameter(LVEDD),left ventricular end-systolic diameter(LVESD)],myocardial injury indicators[N-terminal pro-B-type natriuretic peptide(NT-proBNP),high-sensitivity C reactive protein(hs-CRP)],agglutinin levels,SIRT6 levels,adverse reactions and major adverse cardiovascular events(MACE)were compared between the two groups.Results The total effective rate of the observation group[96.72%(59/61)]was higher than that of the control group[86.89%(53/61)](P<0.05).At 7 d after treatment,compared with the control group,the heart rate,systolic blood pressure and diastolic blood pressure in the observation group were lower,and the urine volume was higher(P<0.01).At 3 months after treatment,LVEDD,LVESD,NT-proBNP,hs-CRP,and agglutinin were lower,while LVEF and SIRT6 were higher in the observation group than in the control group(P<0.01).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After 3 months of follow-up,the incidence of MACE in the observation group was lower than that in the control group(P<0.05).Conclusion The early application of SV demonstrates a significant efficacy in patients with CAHD complicated with AHF,which can improve the hemodynamic status of the body,inhibit ventricular remodeling,regulate the levels of agglutinin and SIRT6,reduce myocardial injury,and reduce the risk of MACE,with a favorable safety profile.